Novel Antidiabetic Medications in Polycystic Ovary Syndrome

• Published in: Discoveries (Craiova, Romania) Vol. 10; no. 1; p. e145
• Main Authors: Somagutta, Manoj Reddy, Jain, Molly, Uday, Utkarsha, Pendyala, Siva K, Mahadevaiah, Ashwini, Mahmutaj, Greta, Jarapala, Nagendrababu, Gad, Mohamed A, Srinivas, Pathan Mayur, Sasidharan, Nayana, Mustafa, Nafisa
• Format: Journal Article
• Language: English
• Published: Romania Applied Systems srl 31.03.2022
• Subjects: Review; Polycystic ovary syndrome; insulin sensitivity; PCOS; incretin; sodium-glucose transporter-2 inhibitors; glucagon-like peptide-1 receptor antagonists; diabetes
• ISSN: 2359-7232; 2359-7232
• DOI: 10.15190/d.2022.4

Polycystic ovary syndrome is a very common endocrine disorder prevalent in premenopausal women. Patients with polycystic ovary syndrome present with abnormal menstruation, ovulation disorders, and hyperandrogenemia. They are often accompanied by insulin resistance, metabolic disorders, and other cardiovascular abnormalities. Also, they have comorbidities, such as dyslipidemia, obesity, diabetes type 2, non-alcoholic fatty liver disease, which all influence the treatment plan. Metformin has been defined as a treatment option in patients with polycystic ovary syndrome. However, the clinical responses to metformin are limited. Thus, the need for novel treatments with a broad range of coverage for the complications is warranted. Sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, incretin analogs are novel drugs approved for treating type-2 diabetes. Because of their recorded benefit with weight loss, improved insulin resistance, and cardiovascular benefits in recent studies, they may help polycystic ovary syndrome women address the polycystic ovary syndrome-related risk of metabolic, reproductive, and psychological consequences. Limited literature is available on the safety and efficacy of these novel antidiabetic drugs in patients with polycystic ovary syndrome. Thus, this review is investigating the role and effectiveness of novel antidiabetic medication as an early therapeutic option in polycystic ovary syndrome.